Electronic commerce system including customized catalog having encoded information
OwnerBruce Verchere, Rusung Tan +2inventors
InventorsBruce Verchere, Rusung Tan, Peter Liston, Robert Korneluk
Life of this patent
Estimating the term…
Loading patent…
OwnerBruce Verchere, Rusung Tan +2inventors
InventorsBruce Verchere, Rusung Tan, Peter Liston, Robert Korneluk
Estimating the term…
The invention features methods for the treatment of diabetes by administering a IAP nucleic acid sequence to a subject. One method includes the steps of (a) providing one or more insulin-producing cells or one or more precursor cells capable of producing progeny cells that produce insulin; (b) transducing the cells with a nucleic acid sequence encoding an IAP polypeptide, the nucleic acid sequence positioned for expression of the IAP polypeptide in the cells, wherein expression of the IAP polypeptide increases survival of the cells relative to untreated control cells; and (c)transplanting the cells from step (b) that have been transduced with a nucleic acid sequence encoding an IAP polypeptide into the individual, wherein the cells produce insulin in amounts sufficient to treat diabetes in the individual.
A method of treating diabetes in a subject in need thereof, said method comprising:
4-5. (canceled)
(canceled)
24-53. (canceled)
57-62. (canceled)
A cell capable of producing insulin or capable of producing progeny cells that produce insulin, wherein said cells express a transgene encoding an IAP polypeptide or fragment thereof, under the control of a constitutive, inducible, or cell-specific promoter, wherein expression of said IAP polypeptide increases survival of said cell relative to an untreated control cell not expressing said IAP.
A medicament for the treatment of diabetes, said medicament comprising a cell capable of expressing insulin or capable of producing progeny cells that produce insulin in an amount sufficient to treat said diabetes, wherein said cell is transduced with a heterologous human XIAP polypeptide or fragment thereof under the control of a constitutive, inducible, or cell-specific promoter, wherein expression of said IAP polypeptide increases survival of said cell relative to an untreated control cell not expressing said IAP.
Dependencies are inferred from the claim text.